What development phase is Eprinex in?

Eprinex is FDA-approved (marketed).

What is the generic name of Eprinex?

EPRINOMECTIN is the generic (nonproprietary) name of Eprinex.

Last reviewed 2026-04-20 · How we verify

Eprinex (EPRINOMECTIN)

FDA-approved active Quality 6/100

Eprinomectin (Eprinex) is a marketed antiparasitic drug that binds to glutamate-gated chloride channels on parasite nerve cells, leading to paralysis and death. A key strength is its unique mechanism of action, which differentiates it in the market. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Generic name	EPRINOMECTIN
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Eprinex CI brief — competitive landscape report
Eprinex updates RSS · CI watch RSS